Effects of oral administration of orodispersible levo-carnosine on quality of life and exercise performance in patients with chronic heart failure
Randomised controlled trialHumans
- Design
- Randomised controlled trial
- Subjects
- 50 patients with stable chronic heart failure and severe left ventricular systolic dysfunction on optimal medical therapy, randomised 1:1
- Dose used in the study
- 500 mg orodispersible L-carnosine once daily added to standard treatment
- Duration
- 6 months
- What was measured
- Left ventricular ejection fraction by echocardiography, cardiopulmonary exercise test (peak VO2, VO2 at anaerobic threshold, peak workload), 6-minute walk distance, and quality of life (EQ-5D and visual analogue scale) at baseline and 6 months.
What the authors reported
In the carnosine group, 6-minute walk distance (P = 0.014) and visual analogue quality-of-life score (P = 0.039) improved between baseline and follow-up. Compared with controls, carnosine was associated with improvement in peak VO2 (P < 0.0001), VO2 at anaerobic threshold, peak workload, 6-minute walk distance and quality of life by EQ-5D and visual analogue scale. The authors concluded carnosine added to conventional therapy has beneficial effects in stable heart failure and said more data are needed on ejection fraction and prognosis.
Limits of this study
Small trial (50 patients), six months. Controls received standard treatment; no placebo is described. Effect on ejection fraction and prognosis not shown. Full text not read.
Source
PubMed 25287762 · doi:10.1016/j.nut.2014.04.021
Entry checked against PubMed abstract (E-utilities) on 2026-10-19. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.